Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Believe Health vs Enhance MD

Believe Health
Site position #454

Lower grade

vs+27.7
Enhance MD
Site position #5

Higher grade

The verdict

Enhance MD takes it — 84.8/100 to 57.1/100.

Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEnhance MD +37
45
82
Dose & formulationEnhance MD +18
64
82
Clinical oversightEnhance MD +26
62
88
Labs & monitoringEnhance MD +39
51
90
FulfillmentEnhance MD +12
72
84
Contract termsEnhance MD +29
55
84
Believe Health · left barEnhance MD · right bar

The numbers

MetricBelieve HealthEnhance MD
WeighScore57.1/10084.8/100
GradeCB
Site position#454#5
SemaglutideNot disclosed$249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay
TirzepatideNot disclosed$329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay
CoverageAll 50 states (claimed; no list published)Not publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Believe Health

Site position #454 · C

Strengths

  • Runs three distinct programs — semaglutide, tirzepatide and a GLP-1 microdose protocol — rather than one product with dose options
  • Publishes a priced peptide catalog with nineteen entries, so at least part of the menu carries figures
  • States clinical hours of Monday to Friday, 9:00 AM to 5:00 PM, and publishes both a phone number and an email address

Where it loses points

  • No semaglutide or tirzepatide price is published anywhere. The figures that exist sit in shipped funnel code that renders on no page, so they are not prices this site will print
  • “The price we quote is the price you pay, period” appears on every treatment page above no quoted price
  • The FAQ question “Where do you operate?” answers itself — “across the states where we operate” — while the homepage counter claims 50 states covered and no list exists
  • Three cancellation notice periods are live at once: 48 hours in the Terms, 30 days in the treatment FAQ, and cancel anytime on the checkout
  • An average rating is published twice at two different values, and a membership count is published with no source, on a site whose Terms are dated June 2026
  • No pharmacy, compounding class, clinician or medical group is named anywhere
  • The microdose program does not name the molecule it contains
Enhance MD

Site position #5 · B

Strengths

  • Transparent tiered pricing across sema, tirz, microdose, and combo
  • Dose-flat — the price does not step up as you titrate
  • Six-month lab testing plus provider-led care
  • NAD+ longevity adjacency available

Where it loses points

  • Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
  • No oral or sublingual route
  • States served are not published
  • Higher entry price than the cheapest compounded programs

Featured provider

Enhance MD

Enhance MD scores 84.8/100 (B). A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard